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ABSTRACT
Phosphatidylinositol 3-kinase (PI3K) pathway activation is associated with 
resistance to paclitaxel in solid tumors. We assessed the safety and activity of 
alpelisib, an oral, selective PI3K p110α inhibitor, plus paclitaxel in patients with 
advanced solid tumors. This Phase Ib, multicenter, open-label, dose-finding study, 
with a planned dose-expansion phase of alpelisib once daily (QD) plus fixed-dose 
paclitaxel, recruited patients with advanced solid tumors. For the dose-finding phase, 
the primary objective was determination of maximum tolerated and/or recommended 
Phase II dose of alpelisib plus paclitaxel, and the secondary objectives included the 
assessment of safety for this combination. From March 2014 to August 2016, 19 
patients with advanced solid tumors were treated with alpelisib QD (300 mg, n=6; 250 
mg, n=4; 150 mg, n=9) plus paclitaxel (80 mg/m2, per standard of care). During dose 
finding, five of 12 (41.7%) evaluable patients for MTD determination experienced 
dose-limiting toxicities: alpelisib 300 mg, Grade 2 hyperglycemia (n=1); alpelisib 
250 mg, Grade 2 hyperglycemia (n=1), Grade 4 hyperglycemia and Grade 3 acute 
kidney injury (n=1); and alpelisib 150 mg, Grade 2 hyperglycemia (n=1) and Grade 
4 leukopenia (n=1). The MTD of alpelisib when administered with paclitaxel was 150 
mg QD. Most frequent all-grade AEs were diarrhea (73.7%; Grade 3/4 10.5%) and 
hyperglycemia (57.9%; Grade 3/4 31.6%). The planned dose-expansion phase was 
not initiated. Alpelisib plus paclitaxel has a challenging safety profile in patients with 
advanced solid tumors. This study was closed following the completion of the dose-
finding phase. Clinical trial registration: ClinicalTrials.gov NCT02051751.
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INTRODUCTION
Although paclitaxel, a taxane-based chemotherapy, 
has been approved as a weekly injection for the treatment 
of several solid tumors [1], most patients develop 
resistance and progressive disease [2, 3]. Resistance to 
paclitaxel has been associated with phosphatidylinositol 
3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) 
pathway activation in vitro and in vivo [4-6]. However, the 
administration of a PI3K inhibitor has increased sensitivity 
in paclitaxel-resistant prostate cancer cells [6]. In addition, 
decreased tumor burden was observed in mice inoculated 
with ovarian cancer cells and treated with a PI3K inhibitor 
plus paclitaxel compared with those treated with paclitaxel 
alone [5].
Activation of the PI3K/mTOR pathway frequently 
occurs via mutations in PIK3CA, which encodes the 
class I PI3K p110α catalytic subunit [7]. Further, 
PIK3CA mutations are among the most frequently 
observed alterations in solid tumors [8-12]. Therefore, 
administration of paclitaxel plus a PI3K p110α-specific 
inhibitor is a potential therapeutic strategy by which to 
delay disease progression in patients with advanced solid 
tumors.
Alpelisib (BYL719) is an oral, selective inhibitor 
of class I PI3K p110α that has shown potent antitumor 
activity in preclinical studies [13, 14]. In a Phase Ia 
study of single-agent alpelisib in patients with advanced 
solid tumors (NCT01219699), a tolerable safety profile 
and encouraging preliminary activity was observed in 
those with PIK3CA-altered (mutation/amplification) 
advanced solid tumors, with the maximum tolerated dose 
(MTD) declared as 400 mg once daily (QD) [15, 16]. 
In addition, single-agent alpelisib was generally well 
tolerated, with the most frequent all-grade, treatment-
related adverse events (AEs; ≥30% of patients) including 
hyperglycemia (51.5%), nausea (50.0%), decreased 
appetite (41.8%), diarrhea (40.3%), and vomiting (31.3%) 
[15, 16]. Hyperglycemia is an expected on-target side 
effect of PI3Kα inhibition given the involvement of 
PI3Kα in glucose homeostasis regulation and occurs 
more frequently with a targeted compound like alpelisib 
compared to pan-PI3K inhibitors or to beta, gamma or 
delta specific PI3K inhibitors. The most frequent all-grade 
AEs (≥30% of patients) reported with a 1-hour intravenous 
(IV) infusion of paclitaxel 80 mg/m2 once weekly (QW) 
included fatigue (47%), alopecia (36%), abdominal pain 
(33%), nausea (31%), and peripheral neuropathy (31%) 
[17].
Here, we report the results from a Phase Ib dose-
finding study, which evaluated the MTD of alpelisib 
QD when administered with paclitaxel in patients with 
advanced solid tumors, and discuss the safety profile of 
this combination.
RESULTS
Patient characteristics and disposition
From March 5, 2014, to August 19, 2016, 19 patients 
with advanced solid tumors were treated with alpelisib QD 
plus paclitaxel during dose finding, as follows: alpelisib 
300 mg (n=6); alpelisib 250 mg (n=4) and alpelisib 150 
mg (n=9). Median age was 57 years and the most common 
primary sites of cancer were breast (26%) and rectum 
(16%). The number of metastatic sites was one or two in 
most patients (Table 1).
At data cut-off (August 19, 2016), all patients had 
discontinued study treatment, primarily due to disease 
progression (63.2%) (Table 2). Three patients (15.8%) 
experienced AEs leading to discontinuation of one or 
both study drugs, as follows: one discontinued both 
drugs due to Grade 3 dehydration, acute kidney injury, 
and hyperglycemia (alpelisib 250 mg cohort); one 
discontinued both drugs due to Grade 4 neutropenia and 
γ-glutamyltransferase increase (alpelisib 150 mg cohort); 
and one discontinued paclitaxel only due to Grade 2 
peripheral neuropathy (alpelisib 150 mg cohort).
Dose finding and dose-limiting toxicities
Of the 12 patients evaluable for MTD determination, 
five (41.7%) experienced DLTs (Table 3): one patient in 
the alpelisib 300 mg cohort; two in the alpelisib 250 mg 
cohort, and two in the alpelisib 150 mg cohort. DLTs 
included leukopenia, hyperglycemia, and acute kidney 
injury. Analysis supported an MTD of alpelisib 150 mg 
QD when administered with paclitaxel 80 mg/m2 QW, 
which had the highest posterior probability of being within 
the target toxicity interval (16%, 35%) while also meeting 
the EWOC criterion.
Safety and tolerability
The median duration of exposure (range) to study 
treatment for each dose level was as follows: alpelisib 
300 mg QD, 8.9 weeks (4.0–16.1); alpelisib 250 mg 
QD, 18.9 weeks (1.0–76.6); and alpelisib 150 mg QD, 
24.1 weeks (8.0–80.1). The most frequent all-grade 
treatment-emergent AEs (≥40% of patients) regardless of 
relationship were diarrhea (n=14 [73.7%]), hyperglycemia 
(n=11 [57.9%]), anemia (n=8 [42.1%]), asthenia (n=8 
[42.1%]), and nausea (n=8 [42.1%]) (Table 4). The most 
frequent Grade 3/4 treatment-emergent AEs (≥10% of 
patients) regardless of relationship were hyperglycemia 
(n=6 [31.6%]), anemia (n=2 [10.5%]), diarrhea (n=2 
[10.5%]), lymphopenia (n=2 [10.5%]), neutropenia (n=2 
[10.5%]), and leukopenia (n=2 [10.5%]) (Table 4).
The most common reason for both alpelisib dose 
reduction and interruption was AEs. The rate of alpelisib 
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dose reduction (at least one) was highest in patients treated 
with alpelisib 300 mg (66.7%), followed by those with 
alpelisib 250 mg (50.0%) and alpelisib 150 mg (22.2%). 
The rate of alpelisib dose interruption was highest in 
patients treated at the 250 mg dose level (75.0%), followed 
by those at both the 300 mg (66.7%) and 150 mg (66.7%) 
dose levels. AEs leading to study drug discontinuation 
were reported in three patients (15.8%). One patient 
discontinued paclitaxel due to Grade 2 neuropathy, but 
continued to receive alpelisib, one patient discontinued 
study treatment due to Grade 4 neutropenia and Grade 
4 gamma-glutamyltransferase increase, and one patient 
discontinued study treatment due to Grade 3 dehydration, 
Grade 3 acute kidney injury, and Grade 2 and Grade 3 
hyperglycemia.
There was one on-treatment death (during treatment 
or within 30 days of last study treatment dose): a patient 
died due to progression of small cell lung cancer on Day 
101, 18 days after the last administration of alpelisib.
Pharmacokinetics
Similar concentration–time profiles of paclitaxel 
were observed in the presence and absence of alpelisib 
and independent of alpelisib dose (Figure 1). The plasma 
drug exposure (area under the curve from time zero to 
infinity [AUCinf] and maximal drug concentration [Cmax]) 
of paclitaxel were comparable on Cycle 1 Day 1 and 
Cycle 1 Day 8, and were independent of dose level, except 
for Cmax for alpelisib 300 mg on Cycle 1 Day 8, which 
Table 1: Patient demographics and disease characteristics at baseline
All patients N=19
Median age, years (range) 57.0 (27.0–76.0)
Male, n (%) 7 (36.8)
Race, n (%)
Caucasian 19 (100)
ECOG performance status, n (%)
0 10 (52.6)
1 9 (47.4)
Primary site of cancer, n (%)
Breast 5 (26.3)
Cartilage 1 (5.3)
Cervix 1 (5.3)
Malignant thymoma 1 (5.3)
Ovary 1 (5.3)
Pancreas 1 (5.3)
Prostate 1 (5.3)
Rectum 3 (15.8)
Small cell lung cancer 1 (5.3)
Soft tissue 1 (5.3)
Stomach 1 (5.3)
Unknown origin 2 (10.5)
Number of metastatic sites, n (%)
1 6 (31.6)
2 8 (42.1)
3 3 (15.8)
≥4 2 (10.5)
ECOG, Eastern Cooperative Oncology Group.
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was lower and more variable (Table 5). Median time to 
maximum concentration (Tmax) of alpelisib on Cycle 1 Day 
8 ranged from 3.17 to 4.17 hours, independent of alpelisib 
dose (Table 5). Cmax and AUC from time zero to 24 
hours (AUC0-24) after the oral administration of alpelisib 
increased in a dose-dependent manner.
Clinical activity
Best overall response and best percentage change 
from baseline per local investigator assessment were 
evaluated in 18 patients with measurable lesions (Figure 
2). Best overall responses were partial response in three 
patients, stable disease in 11 patients and progressive 
disease in four patients.
DISCUSSION
The MTD of alpelisib was 150 mg QD when 
administered with paclitaxel 80 mg/m2 QW in patients 
with solid tumors; however, the overall tolerability of this 
regimen was challenging. In contrast, the MTD of single-
agent alpelisib in a first-in-human study in patients with 
solid tumors was higher at 400 mg QD, with a manageable 
safety profile [15, 16].
Hyperglycemia was the most frequent DLT during 
dose finding, occurring in four of 12 evaluable patients 
(33.3%). In all patients treated with alpelisib 150–300 mg 
QD plus paclitaxel (N=19), hyperglycemia was the most 
frequent Grade 3/4 AE. The occurrence of hyperglycemia 
in the present study was consistent with that in patients 
treated with single-agent alpelisib, where hyperglycemia 
was also the most frequent DLT during dose finding, 
occurring in seven of 68 evaluable patients (10.3%) [16]. 
In patients treated with single-agent alpelisib 30–450 mg 
QD or 120–200 mg twice daily (N=134), hyperglycemia 
was also the most frequent all-Grade AE suspected to 
be treatment related (69 [51.5%]) and Grade 3/4 AE (32 
[23.9%]) [16]. Hyperglycemia is an expected on-target side 
effect of PI3Kα inhibition given the involvement of PI3Kα 
in glucose homeostasis regulation [13-19]. In the present 
study, hyperglycemia was managed with oral antidiabetic 
medications (e.g. metformin; insulin considered for higher 
grades) and dose interruption of alpelisib followed by 
re-starting the same dose or undergoing dose reduction 
depending on the initial grade of hyperglycemia and 
subsequent fasting plasma glucose level. Other AEs were 
Table 2: Patient disposition
All patients N=19
Treatment ongoing, n (%) 0
Treatment discontinued, n (%) 19 (100.0)
Primary reason for treatment discontinuation, n (%)
Disease progression 12 (63.2)
Patient decision 3 (15.8)
Adverse events 2 (10.5)
Physician decision 2 (10.5)
Data cut-off: August 19, 2016.
Table 3: Dose-limiting toxicities in patients treated with alpelisib 150–300 mg QD plus paclitaxel 80 mg/m2 QW
Alpelisib 150 mg QD 
+ paclitaxel
Alpelisib 250 mg QD 
+ paclitaxel
Alpelisib 300 mg QD 
+ paclitaxel
All patients
DLTs, n (%) n=8 n=3 n=1 N=12a
Total 2 (25.0) 2 (66.7) 1 (100) 5 (41.7)
Leukopenia 1 (12.5) 0 0 1 (8.3)
Hyperglycemia 1 (12.5) 2 (66.7)b 1 (100) 4 (33.3)b
Acute kidney injury 0 1 (33.3)b 0 1 (8.3)b
DLTs, dose-limiting toxicities; QD, once daily; QW, once weekly.
a Seven patients were not evaluable due to not experiencing a DLT in Cycle 1 and inadequate drug exposure.
b Grade 4 hyperglycemia and Grade 3 acute kidney injury DLTs were experienced by the same patient.
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managed by concomitant medications and alpelisib dose 
interruption and/or reduction. The rates of dose reduction 
and interruption were high across all dose levels, although 
these rates should be interpreted with caution given 
the small cohort sizes. It should also be noted that the 
administration of corticosteroids as a premedication was 
not standardized, which prevented their contribution 
to the rates of AEs, namely hyperglycemia, from being 
determined. AEs leading to study drug discontinuation 
were reported in three patients; in two of the patients 
these AEs included ones previously reported for weekly 
paclitaxel (peripheral neuropathy and neutropenia) at the 
same dose in this study [20].
Plasma drug exposure to alpelisib increased in a 
dose-dependent manner and was generally comparable 
to the steady-state exposure of single-agent alpelisib at 
similar dose levels [16]. The plasma drug exposure of 
paclitaxel was generally comparable both on Cycle 1 Day 
1 and Cycle 1 Day 8, and was independent of alpelisib 
dose, showing that steady-state exposure of alpelisib 150–
300 mg had no impact on paclitaxel metabolism.
Preliminary efficacy results for alpelisib 150 mg 
QD plus paclitaxel are inconclusive; in a Phase I study, 
single-agent alpelisib exhibited preliminary anti-tumor 
activity in solid tumors from doses of 270 mg QD and 
higher [15, 16]. Therefore, given the challenging safety 
profile of alpelisib plus paclitaxel, the potentially limited 
clinical activity of alpelisib at 150 mg QD [15, 16], and 
the emergence of new treatment options for patients with 
breast cancer, the planned dose-expansion phase of this 
Table 4: Treatment-emergent adverse events (≥20% of all patients, all grades) regardless of relationship to study 
drug
Alpelisib 150 mg + 
paclitaxel (n=9)
Alpelisib 250 mg + 
paclitaxel (n=4)
Alpelisib 300 mg + 
paclitaxel (n=6)
All patients
(N=19)
Adverse events, 
n (%)
Grade ≥3 All-grade Grade ≥3 All-grade Grade ≥3 All-grade Grade ≥3 All-grade
Total 3 (33.3) 9 (100.0) 3 (75.0) 4 (100.0) 5 (83.3) 6 (100) 11 (57.9) 19 (100)
Diarrhea 1 (11.1) 6 (66.7) 0 3 (75.0) 1 (16.7) 5 (83.3) 2 (10.5) 14 (73.7)
Hyperglycemia 1 (11.1) 2 (22.2) 3 (75.0) 4 (100) 2 (33.3) 5 (83.3) 6 (31.6) 11 (57.9)
Anemia 1 (11.1) 6 (66.7) 0 1 (25.0) 1 (16.7) 1 (16.7) 2 (10.5) 8 (42.1)
Asthenia 0 5 (55.6) 0 1 (25.0) 0 2 (33.3) 0 8 (42.1)
Nausea 0 5 (55.6) 0 1 (25.0) 0 2 (33.3) 0 8 (42.1)
Fatigue 0 5 (55.6) 0 0 0 2 (33.3) 0 7 (36.8)
Lymphopenia 1 (11.1) 3 (33.3) 1 (25.0) 2 (50.0) 0 2 (33.3) 2 (10.5) 7 (36.8)
Neutropenia 1 (11.1) 4 (44.4) 0 1 (25.0) 1 (16.7) 2 (33.3) 2 (10.5) 7 (36.8)
Alopecia 0 5 (55.6) 0 0 0 1 (16.7) 0 6 (31.6)
Decreased 
appetite 0 1 (11.1) 0 2 (25.0) 0 3 (50.0) 0 6 (31.6)
Leukopenia 1 (11.1) 3 (33.3) 0 1 (25.0) 1 (16.7) 2 (33.3) 2 (10.5) 6 (31.6)
Weight 
decreased 0 1 (11.1) 0 1 (25.0) 0 4 (66.7) 0 6 (31.6)
Peripheral 
neuropathy 0 4 (44.4) 0 1 (25.0) 0 0 0 5 (26.3)
Peripheral 
edema 0 4 (44.4) 0 0 0 1 (16.7) 0 5 (26.3)
Stomatitis 0 2 (22.2) 0 2 (50.0) 0 1 (16.7) 0 5 (26.3)
Vomiting 0 2 (22.2) 0 2 (50.0) 0 1 (16.7) 0 5 (26.3)
Hypokalemia 1 (11.1) 1 (11.1) 0 2 (50.0) 0 1 (16.7) 1 (5.3) 4 (21.1)
Rash 0 3 (33.3) 0 1 (25.0) 0 0 0 4 (21.1)
Data cut-off: August 19, 2016.
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study was not initiated and the intermittent administration 
of alpelisib not investigated. The present study was 
therefore closed following the completion of the dose-
finding phase.
In contrast to this study, the combination of alpelisib 
with nab-paclitaxel was well tolerated in a Phase I study 
(N=10) [21]. The MTD of alpelisib was not reached and 
the recommended Phase II dose was alpelisib 350 mg daily 
plus nab-paclitaxel 100 mg/m2 IV weekly [21]. Although 
the results need to be verified in a larger cohort, this study 
indicates that adding alpelisib to a taxane may be possible.
Finally, promising disease control and survival 
benefits, with a manageable safety profile, have been 
observed with alpelisib plus fulvestrant in a Phase 
Ib study (NCT01219699) in patients with PIK3CA-
altered estrogen receptor-positive, HER2– advanced 
breast cancer (ABC) [22, 23]. Accordingly, the Phase 
III SOLAR-1 study (NCT02437318) is investigating 
the efficacy and safety of alpelisib 300 mg QD plus 
fulvestrant in patients with PIK3CA-mutant and wild-
type, aromatase inhibitor-resistant, hormone receptor-
positive (HR+), HER2– ABC. Further, the Phase 
II BYLieve study (NCT03056755) is investigating 
the efficacy and safety of alpelisib 300 mg QD plus 
fulvestrant or letrozole in patients with PIK3CA mutant, 
HR+, HER2– ABC, who have progressed on or after 
cyclin-dependent kinase 4/6 inhibitor treatment. The 
challenging safety profile of alpelisib plus paclitaxel 
from the present closed study will help inform ongoing 
studies of alpelisib in combination with other therapies.
Figure 1: Geometric mean and arithmetic mean (SD) concentration-time profiles (pharmacokinetic analysis set). (A) 
paclitaxel by visit and (B) plasma alpelisib by dose level at Cycle 1 Day 8. QD, every day. Data cut-off: August 19, 2016.
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Table 5: Primary pharmacokinetic parameters for paclitaxel at Cycle 1 Day 1 and Cycle 1 Day 8, and alpelisib at 
Cycle 1 Day 8a
Alpelisib 150 mg + paclitaxel Alpelisib 250 mg + paclitaxel Alpelisib 300 mg + paclitaxel
Paclitaxel
C1D1 C1D8 C1D1 C1D8 C1D1 C1D8
AUCinf, 
geometric mean 
ng·hr/ml (CV%) 
[n]
4360 (26.7) 
[7]
4370 (22.8)
 [8]
4320 (43.4) 
[3]
5000 (42.7) 
[2]
5000 (24)
 [5]
4470 (37.8) 
[4]
Cmax, geometric 
mean ng/ml 
(CV%) [n]
2650 (32.8) 
[8]
2790 (26.3) 
[9]
2770 (56.4) 
[3]
2960 (16.1) 
[3]
2700 (19.5) 
[5]
1250 (114)
 [6]
Tmax, median 
hours (range) [n]
1 (0.87–1.17) 
[8]
1 (0.5–1.07)
 [9]
1 (0.45–1.05) 
[3]
0.8 (0.5–1.17) 
[3]
1 (0.5–1.28) 
[5]
0.75 (0–2.67) 
[6]
Alpelisib
C1D8 C1D8 C1D8
AUC
0–24
, 
geometric mean 
ng·hr/ml (CV%) 
[n]
13800 (36.8) [9] 27700 (7.78) [2] 37100 (66.4) [5]
Cmax, geometric 
mean ng/ml 
(CV%) [n]
1390 (63.7) [9] 3750 (51.6) [2] 3000 (63.8) [6]
Tmax, median 
hours (range) [n]
3.17 (1–8.92) [9] 3.23 (2.47–4) [2] 4.17 (3–6) [6]
AUC
0–24
, area-under the curve from time 0 to 24 hours; AUCinf, area-under the curve from time 0 to infinity; C1D1, Cycle 
1 Day 1; C1D8, Cycle 1 Day 8; Cmax, maximal drug concentration; CV, geometric coefficient of variation; Tmax, time to 
maximal drug concentration.
a Pharmacokinetic analysis set.
Data cut-off: August 19, 2016.
Figure 2: Waterfall plot of tumor responses. Best percentage change from baseline in sum of longest diameters and best overall 
response per local investigator assessment. PD, progressive disease; PR, partial response; QD, every day; QW, every week; SD, stable 
disease. *One patient who did not have any target lesion at baseline has been excluded from the graph. Missing bar denotes a missing 
percentage change from baseline. Data cut-off: August 19, 2016.
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MATERIALS AND METHODS
Study design
This Phase Ib, multicenter, open-label, dose-finding 
study explored escalating doses of alpelisib plus fixed-
dose paclitaxel in patients with advanced and unresectable 
solid tumors. A dose-expansion phase was planned in 
patients with human epidermal growth factor receptor 
2-negative (HER2–) locally advanced or metastatic breast 
cancer, or with recurrent or metastatic head and neck 
squamous cell carcinoma (HNSCC) resistant to platinum-
based chemotherapy.
In the dose-finding phase, the primary objective 
was to determine the MTD and/or recommended Phase 
II dose (RP2D) of alpelisib QD when administered with 
paclitaxel 80 mg/m2 QW in patients with advanced solid 
tumors, and the secondary objectives were to assess safety 
and tolerability and to characterize the pharmacokinetic 
(PK) profile.
Patient population
Key inclusion criteria for the dose-finding part of 
the study included age ≥18 years; at least one measurable 
or non-measurable lesion per Response Evaluation Criteria 
In Solid Tumors (RECIST) v1.1; tumor tissue available for 
PI3K signaling analysis; adequate bone marrow and organ 
function; histologically confirmed, advanced unresectable 
solid tumors and progression on (or unable to tolerate) 
standard therapy within 3 months before screening, or 
no available standard anticancer therapy; and Eastern 
Cooperative Oncology Group (ECOG) performance status 
≤2. Prior antineoplastic therapy (including taxanes) was 
permitted provided the patient recovered from related 
side effects to ≤Grade 1. Key exclusion criteria included 
previous treatment with a PI3K or AKT inhibitor (mTOR 
inhibitors allowed); peripheral sensory neuropathy with 
functional impairment (Grade ≥2); impaired cardiac 
function or significant cardiac disease; concurrent 
treatment with medication with a known risk of QT 
prolongation or inducing torsades de pointes; diabetes 
mellitus requiring insulin treatment and/or with clinical 
signs; impaired gastrointestinal (GI) function or GI disease 
that may significantly alter alpelisib absorption; or human 
immunodeficiency virus, active hepatitis B and/or C 
infection.
All patients provided written informed consent. The 
study was conducted in accordance with the Declaration 
of Helsinki and guidelines for Good Clinical Practice, as 
defined by the International Conference on Harmonization.
Protocol amendments
The study was initiated on March 5, 2014. A first 
protocol amendment (June 23, 2014; after six patients 
had been treated) allowed two additional starting doses 
of alpelisib; other amendments included changing the 
permitted fasting plasma glucose value at screening from 
≤140 mg/dL to ≤120 mg/dL, modifying the dose-limiting 
toxicity (DLT) grading of hyperglycemia for consistency 
with Common Terminology Criteria for AEs (CTCAE) 
v4.03, and updating the management of some AEs to 
align with the overall clinical program. The main purpose 
of the second amendment (January 28, 2015; after 14 
patients had been treated) was to modify the guidelines 
for pneumonitis management.
Treatment
Patients received oral alpelisib QD in 28-day 
cycles (300, 250, or 150 mg) and paclitaxel 80 mg/m2 
QW as a 1-hour (±15 minutes) IV infusion after standard 
premedication (per local standard practice). Patients 
received treatment until disease progression, unacceptable 
toxicity, patient decision, death, or discontinuation for any 
other reason.
Assessments
Safety was monitored by physical examination and 
assessment of vital signs, weight, and performance status; 
and by performing electrocardiogram, cardiac imaging, 
ophthalmic, and laboratory evaluations. AEs were assessed 
continuously and graded per CTCAE v4.03. Radiologic 
response was evaluated by computed tomography or 
magnetic resonance imaging by the local investigator 
per RECIST v1.1 at baseline and 8-weekly intervals. PK 
samples for alpelisib were collected from all patients. PK 
samples for paclitaxel were taken on Cycle 1 Day 1/2 
before, during, and after the end of infusion, and again on 
Cycle 1 Day 8/9 after seven doses of alpelisib. Treatment 
with alpelisib was initiated on Cycle 1 Day 2, and PK 
samples were taken during steady state on Cycle 1 Day 
8/9 before, during and after the influence of premedication 
and paclitaxel to assess impact on alpelisib exposure under 
conditions with the highest risk of an interaction.
Analysis sets
Analysis sets were as follows: full analysis set 
(FAS), all patients who received at least one dose of 
alpelisib and/or paclitaxel; safety set, all patients who 
received at least one dose of alpelisib and/or paclitaxel 
and had at least one valid post-baseline safety assessment; 
dose-determining set (DDS), all patients from the 
safety set who during Cycle 1 either met the minimum 
exposure criterion and had sufficient safety evaluations, 
or experienced a DLT; and pharmacokinetic analysis set, 
all patients in the FAS who received at least one dose of 
alpelisib and/or paclitaxel and had at least one evaluable 
concentration measurement.
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Statistical analyses
An adaptive 5-parameter Bayesian logistic 
regression model (BLRM) with escalation with 
overdose control (EWOC) guided the dose-finding 
of each combination [18]. The EWOC principle only 
recommends doses for which the risk of overdosing 
(true DLT rate >0.35) is <25% for the next dose level. 
DLTs were defined as AEs or abnormal laboratory 
values considered to be unrelated to disease, disease 
progression, inter-current illness, or concomitant 
medications that occurred within the first cycle 
of treatment and met any of the criteria listed in 
Supplementary Table 1. AEs that did not meet the 
criteria within Supplementary Table 1 but led to a dose 
interruption of alpelisib for >7 consecutive days, or 
paclitaxel for ≥2 consecutive doses within Cycle 1, or 
between Cycle 1 and Cycle 2 Day 1, were also defined 
as DLTs. Available data were analyzed after Cycle 1 per 
cohort of patients to decide the dose for the next cohort 
and/or determine the MTD/RP2D. MTD estimation was 
based on the dose-dependent incidence rate of DLTs in 
Cycle 1 for patients of the DDS using the BLRM with 
EWOC principle.
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